Literature DB >> 23352418

Postoperative surveillance for non-small cell lung cancer resected with curative intent: developing a patient-centered approach.

Nathan M Mollberg1, Mark K Ferguson.   

Abstract

Local recurrence or the development of metachronous cancer after surgical therapy for early-stage non-small cell lung cancer (NSCLC) is not uncommon, and these conditions are often amenable to curative therapy. Predictors of recurrence based on surgical, patient, and pathologic factors are well known. A literature search was performed for articles regarding identification or treatment with curative intent of early local recurrence or metachronous cancer after resection of NSCLC. A patient-centered algorithm for surveillance after resection can be developed based on both risk of recurrence and potential benefit from further treatment to optimize individual follow-up algorithms.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23352418     DOI: 10.1016/j.athoracsur.2012.09.075

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  11 in total

1.  Cons: long-term CT-scan follow-up is not the standard of care in patients curatively treated for an early stage non-small cell lung cancer.

Authors:  Jan P van Meerbeeck; Halil Sirimsi
Journal:  Transl Lung Cancer Res       Date:  2015-08

2.  Pros: long-term CT scan follow-up should be the standard of care in patients who are curatively treated for an early-stage non-small cell lung cancer.

Authors:  Waël C Hanna
Journal:  Transl Lung Cancer Res       Date:  2015-08

3.  Imaging Surveillance for Surgically Resected Stage I Non-Small Cell Lung Cancer: Is More Always Better?

Authors:  Melanie Subramanian; Jingxia Liu; Caprice Greenberg; Jessica Schumacher; George J Chang; Timothy L McMurry; Amanda B Francescatti; Tara R Semenkovich; Jessica L Hudson; Bryan F Meyers; Varun Puri; Benjamin D Kozower
Journal:  J Thorac Cardiovasc Surg       Date:  2018-10-24       Impact factor: 5.209

4.  Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer.

Authors:  Feiran Lou; Camelia S Sima; Valerie W Rusch; David R Jones; James Huang
Journal:  Ann Thorac Surg       Date:  2014-08-07       Impact factor: 4.330

5.  Characteristics and timing of recurrence during postoperative surveillance after curative resection for lung adenocarcinoma.

Authors:  Terumoto Koike; Tatsuya Goto; Akihiko Kitahara; Seijiro Sato; Masayuki Saitoh; Takehisa Hashimoto; Osamu Namura; Masashi Takahashi; Shin-Ichi Toyabe; Masanori Tsuchida
Journal:  Surg Today       Date:  2017-05-04       Impact factor: 2.549

6.  Second primary lung cancers: smokers versus nonsmokers after resection of stage I lung adenocarcinoma.

Authors:  R Taylor Ripley; Robert R McMillan; Camelia S Sima; Saad M Hasan; Usman Ahmad; Feiran Lou; David R Jones; Valerie W Rusch; Nabil P Rizk; James Huang
Journal:  Ann Thorac Surg       Date:  2014-07-16       Impact factor: 4.330

7.  Predictors of imaging surveillance for surgically treated early-stage lung cancer.

Authors:  Leah M Backhus; Farhood Farjah; Steven B Zeliadt; Thomas K Varghese; Aaron Cheng; Larry Kessler; David H Au; David R Flum
Journal:  Ann Thorac Surg       Date:  2014-10-03       Impact factor: 4.330

8.  Stage II-IV lung cancer cases with lymphovascular invasion relapse within 2 years after surgery.

Authors:  Satoshi Shiono; Naoki Kanauchi; Naoki Yanagawa; Masami Abiko; Toru Sato
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-11-02

9.  Spread through air spaces in lung cancer patients is a risk factor for pulmonary metastasis after surgery.

Authors:  Satoshi Shiono; Makoto Endo; Katsuyuki Suzuki; Kazuki Hayasaka; Naoki Yanagawa
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

Review 10.  Integrated Palliative Care and Oncologic Care in Non-Small-Cell Lung Cancer.

Authors:  Divya Chandrasekar; Erika Tribett; Kavitha Ramchandran
Journal:  Curr Treat Options Oncol       Date:  2016-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.